Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations

Oh, Hakumei; Loberiza, Fausto R.; Zhang, Mei Jie; Ringdén, Olle; Akiyama, Hideki; Asai, Takayoshi; Miyawaki, Shuichi; Okamoto, Shinichiro; Horowitz, Mary M.; Antin, Joseph H.; Bashey, Asad; Bird, Jennifer M.; Carabasi, Matthew; Fay, Joseph W.; Gale, Robert Peter; Giller, Roger; Goldman, John M.; Hale, Gregory A.; Harris, Richard E.; Henslee-Downey, Jean; Kolb, Hans Jochem; Litzow, Mark R.; McCarthy, Philip L.; Neudorf, Steven; Serna, Derek S.; Socié, Gérard; Tiberghien, Pierre; Barrett, A. John

doi:10.1182/blood-2004-06-2385

Cited by 147 publications

(109 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, the Japanese population has a homogeneous genetic background and incidence and severity of GVHD is considered to be lower than that in western populations even in HSCT from MSD. 12 Recently, Rizzo et al 13 reported there are, in respect of risk factors, two types of LM after HSCT. The squamous cell carcinoma of the skin and oral cavity are clearly related with GVHD, whereas the non-squamous cell carcinoma is not related with GVHD.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan

Kikuchi

Yabe

Katô³

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

We report long-term outcomes of 329 childhood severe aplastic anemia (SAA) patients who underwent hematopoietic SCT (HSCT) from an HLA-matched sibling donor in the Japanese Hematopoietic Cell Transplantation Registry. OS and EFS at 10 years were as high as 89.7 þ / À 1.7% and 85.5 þ / À 2.0%, respectively. Five cases of late malignancies (LM) were identified (malignant peripheral nerve sheath tumor, thyroid carcinoma, colon carcinoma, MDS and hepatoblastoma). Cumulative incidence of LM was 0.8% at 10 years and 2.5% at 20 years, respectively, which was lower than that in previous reports. This low incidence is in keeping with the low occurrence of skin cancer in Japanese population and of acute GVHD in our study group. Radiation-containing conditioning was not significantly associated with the incidence of LM after HSCT probably because of absolute low patient number who developed LM in our series. In terms of LM development after HSCT, low-dose TBI in HSCT for SAA to avoid graft rejection, which is commonly used in Japan, might be tolerable in the Japanese population because of its low incidence. Keywords: aplastic anemia; childhood; hematopoietic SCT; long-term outcome; late malignancies INTRODUCTION Aplastic anemia is a hematopoietic disorder characterized by pancytopenia and BM hypoplasia. Therapeutic options for severe aplastic anemia (SAA) are immunosuppressive therapy and hematopoietic SCT (HSCT). In children, if an HLA-matched sibling donor (MSD) is available, HSCT is the first line of therapy for SAA. HSCT from MSD is an established standard therapy for SAA in children and high survival rates have already been reported. However, little is known about long-term outcomes of these children.Late malignancies (LM) are serious complications for patients who undergo HSCT. 3,4 In SAA, LM are also reported in the patients with HSCT and its occurrence is related to radiation-containing conditioning regimen and GVHD grade in adults, 5,6 however, the incidence and prognostic factors of LM in children with SAA who undergo HSCT are totally unknown.In this article, we report long-term outcomes of childhood SAA patients who underwent HSCT from MSD in the centers of the Japanese Hematopoietic Cell Transplantation Registry and describe the occurrence of LM.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan

Kikuchi

Yabe

Katô³

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…For example, regionalization and specialization has been shown to reduce TRM as well as acute and chronic GVHD. 22,23 In order to address this crucial question, we included three sibling case-control pairs in our study, all diagnosed with MLD. Thus, we were able to compare progression of the untreated disease with that in a sibling with the same mutations who had undergone HSCT.…”

Section: Discussionmentioning

confidence: 99%

Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy

Solders

Martin

Andersson

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

In metachromatic leukodystrophy (MLD), the deficiency of the lysosomal enzyme arylsulfatase A (ARSA) leads to demyelination in the central and peripheral nervous system and ultimately to death. Allogeneic hematopoietic SCT (HSCT) is currently the only treatment for adult and late-onset juvenile MLD, although it is still in question because of insufficient follow-up. We wanted to determine whether HSCT could halt the progression of adult and late-onset juvenile MLD. Four treated unrelated patients and three untreated siblings were included in the study, and followed regularly for up to 18 years after transplantation. The patients were assessed from clinical examination, ARSA enzyme levels, magnetic resonance imaging of the brain and neuropsychological and neurophysiological tests. In the treated patients, ARSA levels were normal up to 18 years after transplantation. The parameters evaluated stabilized and remained stable after a latency period of 12-24 months. Two patients live normal lives, partially in a protected environment. The other two patients stabilized at a low cognitive and functional level. One of the controls is demented, one is in a vegetative state and one died. We conclude that, in comparison with their untreated siblings, HSCT halted the progression of the disease in our treated patients.

show abstract

“…All of the patients in our study were Japanese, and many of them (75%) had received BM as a stem-cell graft. It is known that Japanese patients have a lower risk of developing acute GVHD, 30 and that BMT is associated with a decrease in the development of acute GVHD. 31 Without haplotype C-A-A ( Thus, the ethnic population or the stem-cell source might also affect the association between CTLA-4 polymorphisms and the development of acute GVHD.…”

Section: Discussionmentioning

confidence: 99%

Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT

Murase

Nishida

Onizuka

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations

Cited by 147 publications

References 18 publications

Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan

Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan

Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy

Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT

Contact Info

Product

Resources

About